Adare Pharmaceuticals: Optimizing therapeutic performance. Creating new possibilities for patients.
When it comes to optimizing the therapeutic performance of oral drugs, customizing drug release profiles can provide a number of benefits, including improved efficacy, enhanced safety, and reduced dosing frequency. Adare has several proprietary technologies that can be used to customize drug release profiles and optimize the therapeutic performance of oral drugs.
When it comes to optimizing the therapeutic performance of oral drugs, customizing drug release profiles can provide a number of benefits, including improved efficacy, enhanced safety, and reduced dosing frequency.
Adare has several proprietary technologies that can be used to customize drug release profiles and optimize the therapeutic performance of oral drugs.
Diffucaps® Customized Release Technology
This technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This multiparticulate system provides sophisticated control of drug delivery and optimizes release profiles for single drugs and drug combinations.
Examples of customized release particles
Eurand Minitabs® Controlled Release Technology
This technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. A significant advantage of Eurand Minitabs® technology is the ability for the patient or caregiver to open the capsule and sprinkle the contents on soft foods or add to a liquid. This is especially helpful for the pediatric patient, the elderly patient, or anyone who has difficulty swallowing.
With a broad range of proprietary technologies, Adare can help you overcome formulation challenges. To learn more, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com .
©2015 Adare Pharmaceuticals, Inc.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Cooperating With Our Customers Across the US
May 13th 2025Highlighting the importance for our clients to prepurchase multi-year maintenance contracts, in order to avoid their machines breaking or stopping to work suddenly and unexpectedly, to minimize the risk of interrupted production and emergency maintenance costs.
